No biomarker	T Acute Lymphoblastic Leukemia	No biomarker	T Acute Lymphoblastic Leukemia	nelarabine Sensitive: A1 - Approval Businesswire - 3 weeks (New A1) nelarabine Sensitive : A1 Businesswire - 3wk	nelarabine Sensitive: A1 - Approval Businesswire - 3 weeks nelarabine Sensitive : A1 Businesswire - 3 weeks - (New A1)
No biomarker	T Acute Lymphoblastic Leukemia	No biomarker	T Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + nelarabine Sensitive : A2	cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + nelarabine Sensitive : A2
No biomarker	T Acute Lymphoblastic Leukemia	No biomarker	T Acute Lymphoblastic Leukemia	vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive : A2	vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive : A2
TP53 mutation	T Acute Lymphoblastic Leukemia	TP53 mutation	T Acute Lymphoblastic Leukemia	venetoclax Sensitive: C1 - Off-label venetoclax Sensitive : C1	venetoclax Sensitive: C1 - Off-label venetoclax Sensitive : C1
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
FBXW7 mutation	T Acute Lymphoblastic Leukemia	FBXW7 mutation	T Acute Lymphoblastic Leukemia	prednisone Resistant: C3 – Early Trials prednisone Resistant : C3	prednisone Resistant: C3 – Early Trials prednisone Resistant : C3
HGF-L	T Acute Lymphoblastic Leukemia	HGF-L	T Acute Lymphoblastic Leukemia	mogamulizumab Resistant: C3 – Early Trials mogamulizumab Resistant : C3	mogamulizumab Resistant: C3 – Early Trials mogamulizumab Resistant : C3
NOTCH1 L1574Q	T Acute Lymphoblastic Leukemia	NOTCH1 L1574Q	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 V1577E	T Acute Lymphoblastic Leukemia	NOTCH1 V1577E	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 L1600Q	T Acute Lymphoblastic Leukemia	NOTCH1 L1600Q	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 L1585R	T Acute Lymphoblastic Leukemia	NOTCH1 L1585R	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 V1577A	T Acute Lymphoblastic Leukemia	NOTCH1 V1577A	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 L1600P	T Acute Lymphoblastic Leukemia	NOTCH1 L1600P	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 L1574P	T Acute Lymphoblastic Leukemia	NOTCH1 L1574P	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 F1592S	T Acute Lymphoblastic Leukemia	NOTCH1 F1592S	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 F1592C	T Acute Lymphoblastic Leukemia	NOTCH1 F1592C	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
JAK3 mutation	T Acute Lymphoblastic Leukemia	JAK3 mutation	T Acute Lymphoblastic Leukemia	tofacitinib Resistant: C4 – Case Studies tofacitinib Resistant : C4	tofacitinib Resistant: C4 – Case Studies tofacitinib Resistant : C4
SET-NUP214 fusion	T Acute Lymphoblastic Leukemia	SET-NUP214 fusion	T Acute Lymphoblastic Leukemia	ADE Sensitive: C4 – Case Studies ADE Sensitive : C4	ADE Sensitive: C4 – Case Studies ADE Sensitive : C4
FGFR1 rearrangement + Chr t(8;13)	T Acute Lymphoblastic Leukemia	FGFR1 rearrangement + Chr t(8;13)	T Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor Resistant: C4 – Case Studies Tyrosine kinase inhibitor Resistant : C4	Tyrosine kinase inhibitor Resistant: C4 – Case Studies Tyrosine kinase inhibitor Resistant : C4
TP53 mutation	T Acute Lymphoblastic Leukemia	TP53 mutation	T Acute Lymphoblastic Leukemia	CD7-targeted CAR-T immunotherapy Sensitive: C4 – Case Studies CD7-targeted CAR-T immunotherapy Sensitive : C4	CD7-targeted CAR-T immunotherapy Sensitive: C4 – Case Studies CD7-targeted CAR-T immunotherapy Sensitive : C4
MEF2C overexpression	T Acute Lymphoblastic Leukemia	MEF2C overexpression	T Acute Lymphoblastic Leukemia	ABT-737 Sensitive: D – Preclinical ABT-737 Sensitive : D	ABT-737 Sensitive: D – Preclinical ABT-737 Sensitive : D
PAK2 overexpression	T Acute Lymphoblastic Leukemia	PAK2 overexpression	T Acute Lymphoblastic Leukemia	FRAX597 + PF-3758309 Sensitive: D – Preclinical FRAX597 + PF-3758309 Sensitive : D	FRAX597 + PF-3758309 Sensitive: D – Preclinical FRAX597 + PF-3758309 Sensitive : D
MCL1 underexpression	T Acute Lymphoblastic Leukemia	MCL1 underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D
MYC underexpression	T Acute Lymphoblastic Leukemia	MYC underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D
CCND3 deletion	T Acute Lymphoblastic Leukemia	CCND3 deletion	T Acute Lymphoblastic Leukemia	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
JAK3 M511I	T Acute Lymphoblastic Leukemia	JAK3 M511I	T Acute Lymphoblastic Leukemia	tofacitinib XR Sensitive: D – Preclinical tofacitinib XR Sensitive : D	tofacitinib XR Sensitive: D – Preclinical tofacitinib XR Sensitive : D
JAK3 M511I	T Acute Lymphoblastic Leukemia	JAK3 M511I	T Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	CB-839 Sensitive: D – Preclinical CB-839 Sensitive : D	CB-839 Sensitive: D – Preclinical CB-839 Sensitive : D
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	IACS-010759 Sensitive: D – Preclinical IACS-010759 Sensitive : D	IACS-010759 Sensitive: D – Preclinical IACS-010759 Sensitive : D
BCL2L1 underexpression	T Acute Lymphoblastic Leukemia	BCL2L1 underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D
PRC2 mutation	T Acute Lymphoblastic Leukemia	PRC2 mutation	T Acute Lymphoblastic Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
PCDHB15 overexpression	T Acute Lymphoblastic Leukemia	PCDHB15 overexpression	T Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
NUP214-ABL1 rearrangement	T Acute Lymphoblastic Leukemia	NUP214-ABL1 rearrangement	T Acute Lymphoblastic Leukemia	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D

T Acute Lymphoblastic Leukemia

Associations(38)

Associations
(38)